Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Contract Formulation Company Profile – Glatt Air Techniques, Inc.

By Drug Discovery Trends Editor | February 27, 2009

Glatt Air Techniques, Inc.
Glatt Air Techniques, Inc.

Headquarters
Ramsey, New Jersey

Location(s)
Ramsey, New Jersey

Years in Drug Formulation
20 Years

Spokesperson
Gary Selander

Web site 

Areas of research

•

Small Molecule  

Biological  

Other

 

Drug Formulation Services Offered
• Analytical method development    • Bioavailability enhancement

•

Compatibility studies of active ingredients   

•

Dosage form selection

•

Excipient compatibility   

•

Formulation optimization

•

Formulation stress testing   

in silico studies

•

Manufacture of clinical supplies   

Novel delivery system

Packaging compatibility assessment   

Particle size reduction

Preclinical studies   

Solubilizing water-insoluble drugs

•

Stability studies   

•

Taste masking/flavorings

 

 

 

 

 

 

 

 

 

Other Services Offered
Disease Research    Target Identification

Lead Identification   

Early Safety Tests

Lead Optimization   

Pre-clinical Studies

•

IND Submission   

Clinical Trials

NDA Submission   

Post-marketing Studies

•

ANDA Submission   

 

 

 

 

 

 

 

 

 

Types of Drugs

•

Generics  

•

Prescription  

•

OTC

 

Dosage Forms
• Capsules    Implantable

Inhalation   

Injectible

•

Oral   

Parenteral

Peptide and Protein   

•

Tablets

•

Topical   

 

 

 

 

 

 

Company’s role in drug discovery and developmnet
Glatt Air Techniques is dedicated to the development of solid, oral dosage forms from pre-formulation studies through commercial scale, GMP production. Our efforts are supported by a modern facility equipped to produce feasibility batches as small as 500 grams and scale up, potentially, to commercial batches of 2 metric tons.

Company’s experience and expertise in drug formulation
Glatt Air Techniques has extensive experience in the development and production of the “hard to craft”, modified release dosage form. We are particularly adept at pellet development through drug layering processes in Wurster inserts, as well direct spheronization through our proprietary CPS process. We are also offering an excellent ODT technology platform. We welcome opportunities that challenge us.

Relationship with pharma companies
With Glatt Air Techniques, Inc., drug formulation and contract manufacturing opportunities may take the form of a business partnership or may operate as a more conventional, fee for service agreement. We feel that offering our services on a flexible basis allows us appeal to a wider client base.

Factors critical for drug formulation
For the generic product, nothing will trump speed, a great biostudy match and economy of production. For the new drug, a thorough comprehension of the basics is essential, i.e., solubility profiling, BCS class, morphology / polymorphism studies, potential for ionization, site of absorption, excipient compatibility study, etc.. Here, the homework is what leads to success.

Business/regulatory trends impacting drug formulation
We see a clear trend towards the development of multiple API dosage forms, an increasing emphasis on fewer dosage forms to be taken over time, and a frequent need to control the morphology of the dosage form during the production process. These issues,and the frequent desire to legally circumvent dosage form patents, are driving the need for formulation and production innovation. Additionally, we see the demand for ODT formulations as an area of considerable opportunity.

The continuing globalization of the industry is driving the demand for development and production compliance with multiple agencies at once.


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE